A SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT2) MAY CURE MORE THAN 40% PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Introduction: Relapse of a malignant hematological disease after allogeneic HCT is associated with poor survival and may not be treated with a curative intent. However, a second HCT (HCT2) may achieve durable remission. Objective: To determine the outcomes of pediatric patients who received a HCT2 f...

Celý popis

Podrobná bibliografie

Hlavní autoři:	MF Cardoso, G Zamperlini, CNM Breviglieri, R Gouveia, VC Ginani, JF Marques, LL Quintino, LDS Domingues, MGAD Matos, A Seber
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-10-01
Edice:	Hematology, Transfusion and Cell Therapy
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2531137923011574
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!